Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie for å vurdere endring i sykdomsaktivitet, uønskede hendelser og hvordan stoffet beveger seg gjennom kroppen hos voksne deltakere som lever med humant immunsviktvirus (HIV) som får intravenøs (IV) infusjon av Buigalimab og/eller ABBV-382

4. november 2026 oppdatert av: AbbVie

En fase 2, multisenter, randomisert, dobbeltblind, placebokontrollert studie for å evaluere effektivitet, sikkerhet, tolerabilitet og farmakokinetikk av Buigalimab og/eller ABBV-382 hos mennesker som lever med HIV på stabil antiretroviral terapi som gjennomgår analytisk behandlingsavbrudd

Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV disease is considered to be a chronic disease requiring lifelong therapy. The purpose of this study is to assess change in disease activity, adverse events, tolerability, and how the drug moves through the body.

Budigalimab and ABBV-382 are investigational drugs being developed for the treatment of HIV disease. In Part 1, participants are placed in 1 of 5 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 7 chance that participants will be assigned to placebo (A placebo is not a drug and it is not expected to have any chemical effects on your body and it is not designed to treat any disease or illness). In Part 2, eligible participants will be placed in an open-label arm to receive Budigalimab. Approximately 160 adult participants living with HIV disease on stable antiretroviral therapy (ART) willing to undergo Analytical Treatment Interruption (ATI) will be enrolled at approximately 90 sites worldwide.

In Part 1, participants will receive 4 doses of intravenous (IV) budigalimab or placebo combined with 3 doses of IV ABBV-382 or placebo for an 8 week dosing period. In Part 2, participants will receive 4 doses of open-label subcutaneous (SC) Budigalimab for a 6 week dosing period. Participants need to be stable on antiretroviral therapy to participate in the study. If participant qualifies to the study, on the day they receive the first injection, participants will be asked to stop antiretroviral medications (also referred to as analytical treatment interruption or ATI) for 112 weeks or until meeting specific criteria to restart antiretroviral medications. Participants will undergo a closely monitored ART interruption. Protocol-defined ART restart criteria includes participant's request. Participants will be followed for up to approximately 112 weeks.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. There will be an option for virtual or home health visits for some of the follow-up visits. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

163

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Brussels Capital
      • Anderlecht, Brussels Capital, Belgia, 1070
        • Universite Libre de Bruxelles - Hopital Erasme /ID# 257433
      • Brussels, Brussels Capital, Belgia, 1000
        • CHU Saint Pierre /ID# 257447
      • Brussels, Brussels Capital, Belgia, 1200
        • Cliniques Universitaires UCL Saint-Luc /ID# 257444
    • Oost-Vlaanderen
      • Ghent, Oost-Vlaanderen, Belgia, 9000
        • UZ Gent /ID# 257446
    • São Paulo
      • São Paulo, São Paulo, Brasil, 04037-030
        • Ricardo Diaz Scientific Solution /ID# 257335
    • British Columbia
      • Vancouver, British Columbia, Canada, V6Z 2T1
        • Spectrum Health Vancouver /ID# 260791
    • Ontario
      • Ottawa, Ontario, Canada, K1H 8L6
        • Ottawa Hospital Research Institute /ID# 256993
      • Toronto, Ontario, Canada, M5G 2C4
        • Duplicate_Toronto General Hospital /ID# 256994
    • Quebec
      • Montreal, Quebec, Canada, H4A 3J1
        • McGill University Health Centre - Glen Site. /ID# 256992
      • Québec, Quebec, Canada, G1V 4G2
        • CHU de Quebec-Université Laval hôpital CHUL /ID# 261611
    • Saskatchewan
      • Regina, Saskatchewan, Canada, S4P 0W5
        • Regina General Hospital - Infectious Disease Clinic /ID# 260243
    • Alabama
      • Birmingham, Alabama, Forente stater, 35222-2309
        • University of Alabama at Birmingham, 1917 Research Clinic /ID# 257549
    • California
      • Bakersfield, California, Forente stater, 93301
        • Franco Felizarta, Md /Id# 256927
      • Beverly Hills, California, Forente stater, 90211
        • AHF Research Center /ID# 257025
      • Long Beach, California, Forente stater, 90813-3267
        • Long Beach Education and Research Consultants /ID# 257552
      • Los Angeles, California, Forente stater, 90027
        • AHF Healthcare Center- Hollywood /ID# 257026
      • Los Angeles, California, Forente stater, 90028-6213
        • Los Angeles LGBT Center /ID# 258407
      • Los Angeles, California, Forente stater, 90036
        • Ruane Clinical Research Group /ID# 256932
      • Palm Springs, California, Forente stater, 92262
        • Palmtree Clinical Research Inc. /Id# 258409
      • San Francisco, California, Forente stater, 94102
        • Optimus Medical /ID# 257182
      • San Francisco, California, Forente stater, 94115-3037
        • Quest Clinical Research /ID# 256928
    • District of Columbia
      • Washington D.C., District of Columbia, Forente stater, 20017
        • Washington Health Institute /ID# 259336
    • Florida
      • DeLand, Florida, Forente stater, 32720-0920
        • Midland Florida Clinical Research Center /ID# 257101
      • Fort Lauderdale, Florida, Forente stater, 33308
        • Ahf Healthcare Center - Northpoint /ID# 256934
      • Ft. Pierce, Florida, Forente stater, 34982
        • Midway Immunology and Research Center /ID# 256930
      • Miami, Florida, Forente stater, 33147
        • Advanced Pharma CR, LLC /ID# 259335
      • Orlando, Florida, Forente stater, 32803
        • Orlando Immunology Center /ID# 256931
      • Orlando, Florida, Forente stater, 32806-3300
        • Bliss Health /ID# 257827
      • Tampa, Florida, Forente stater, 33614
        • Baycare Medical Group - Tampa /ID# 256953
      • Vero Beach, Florida, Forente stater, 32960-6541
        • The Pierone Research Institute /ID# 257022
      • West Palm Beach, Florida, Forente stater, 33407
        • Triple O Research Institute /ID# 256929
    • Georgia
      • Atlanta, Georgia, Forente stater, 30308
        • Winship At Emory University Hospital Midtown /ID# 258410
      • Decatur, Georgia, Forente stater, 30033
        • Metro Infectious Disease Consultants /ID# 256955
    • Illinois
      • Chicago, Illinois, Forente stater, 60613-2010
        • Howard Brown Health Center /ID# 257485
    • Massachusetts
      • Springfield, Massachusetts, Forente stater, 01105-1406
        • Claudia T. Martorell MD LLC dba The Research Institute /ID# 259155
    • Missouri
      • Kansas City, Missouri, Forente stater, 64111
        • KC CARE Health Center - Midtown South /ID# 257178
    • Nevada
      • Las Vegas, Nevada, Forente stater, 89106
        • Las Vegas Research Center /ID# 257619
    • New Jersey
      • Camden, New Jersey, Forente stater, 08103
        • Cooper University Health Care - Camden /ID# 258133
      • Newark, New Jersey, Forente stater, 07102
        • Saint Michael's Medical Center /ID# 258802
      • Somers Point, New Jersey, Forente stater, 08244
        • South Jersey Infectious Disease /ID# 257840
    • New Mexico
      • Albuquerque, New Mexico, Forente stater, 87106
        • The University of New Mexico /ID# 257533
    • New York
      • Syracuse, New York, Forente stater, 13215
        • Suny Upstate University Hospital Community Campus /ID# 257847
      • The Bronx, New York, Forente stater, 10461
        • Jacobi Medical Center /ID# 257849
      • The Bronx, New York, Forente stater, 10467
        • Montefiore Medical Center /ID# 257792
    • North Carolina
      • Greenville, North Carolina, Forente stater, 27834
        • East Carolina University - Brody School of Medicine /ID# 257544
      • Winston-Salem, North Carolina, Forente stater, 27157
        • Atrium Health Wake Forest Baptist Medical Center /ID# 257542
    • Texas
      • Austin, Texas, Forente stater, 78705-3326
        • Central Texas Clinical Research /ID# 256920
      • Dallas, Texas, Forente stater, 75208-4599
        • Prism Health North Texas - Oak Cliff Health Center /ID# 256933
      • Dallas, Texas, Forente stater, 75246
        • North Texas Infectious Diseases Consultants, P.A /ID# 257592
      • Dallas, Texas, Forente stater, 75390-7208
        • University of Texas Southwestern Medical Center /ID# 257551
      • Fort Worth, Texas, Forente stater, 76104
        • Texas Center for Infectious Disease Associates /ID# 257183
      • Houston, Texas, Forente stater, 77098-3900
        • The Crofoot Research Center, Inc /ID# 256921
      • Longview, Texas, Forente stater, 75605
        • DCOL Center for Clinical Research /ID# 257093
    • Wisconsin
      • Milwaukee, Wisconsin, Forente stater, 53226
        • Wisconsin Medical Center /ID# 257498
      • Paris, Frankrike, 75012
        • AP-HP - Hopital Saint-Antoine /ID# 258090
      • Paris, Frankrike, 75020
        • AP-HP - Hopital Tenon /ID# 258091
      • Modena, Italia, 41124
        • Azienda Ospedaliero-Universitaria di Modena /ID# 257411
    • Milano
      • Milan, Milano, Italia, 20132
        • IRCCS Ospedale San Raffaele /ID# 259820
      • Milan, Milano, Italia, 20162
        • ASST Grande Ospedale Metropolitano Niguarda /ID# 257410
    • Napoli
      • Naples, Napoli, Italia, 80131
        • Azienda Ospedaliera Universitaria Federico II - Naples /ID# 257412
      • Tokyo, Japan, 108-8639
        • IMSUT Hospital, The Institute of Medical Science, The University of Tokyo /ID# 265344
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan, 460-0001
        • NHO Nagoya Medical Center /ID# 261433
    • Osaka
      • Osaka, Osaka, Japan, 540-0006
        • National Hospital Organization Osaka National Hospital /ID# 261520
    • Kuyavian-Pomeranian Voivodeship
      • Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polen, 85-030
        • Wojewodzki Szpital Obserwacyjno-Zakazny im. Tadeusza Browicza /ID# 259184
    • Pomeranian Voivodeship
      • Gdansk, Pomeranian Voivodeship, Polen, 80-405
        • Punkt Zdrowia /ID# 257950
      • San Juan, Puerto Rico, 00909-1711
        • Clinical Research Puerto Rico /ID# 256956
      • San Juan, Puerto Rico, 00909
        • HOPE Clinical Research /ID# 257487
      • Barcelona, Spania, 08036
        • Hospital Clinic de Barcelona /ID# 257269
      • Madrid, Spania, 28034
        • Hospital Universitario Ramon y Cajal /ID# 257266
      • Madrid, Spania, 28046
        • Hospital Universitario La Paz /ID# 257170
    • Barcelona
      • Badalona, Barcelona, Spania, 08916
        • Hospital Universitario Germans Trias i Pujol /ID# 257268
    • Greater London
      • London, Greater London, Storbritannia, NW3 2QG
        • Royal Free Hospital /ID# 257453
      • London, Greater London, Storbritannia, SE1 9RT
        • Dup_Guys and St Thomas NHS Foundation Trust - Guy's Hospital /ID# 257761
    • Gauteng
      • Johannesburg, Gauteng, Sør-Afrika, 2001
        • Wits RHI Research Centre /ID# 257354
      • Johannesburg, Gauteng, Sør-Afrika, 2013
        • Perinatal HIV Research Unit (PHRU) /ID# 257350
      • Johannesburg, Gauteng, Sør-Afrika, 2092
        • Clinical HIV Research Unit (CHRU) /ID# 257358
      • Johannesburg, Gauteng, Sør-Afrika, 2193
        • Ezintsha Research Centre /ID# 257391
      • Berlin, Tyskland, 10439
        • zibp-Zentrum fuer Infektiologie /ID# 257110
    • Hesse
      • Frankfurt am Main, Hesse, Tyskland, 60596
        • Infektiologikum /ID# 257112
    • North Rhine-Westphalia
      • Bonn, North Rhine-Westphalia, Tyskland, 53127
        • Universitaetsklinikum Bonn /ID# 257113

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 70 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • A condition of general good health in the opinion of the investigator, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG).
  • Must be on antiretroviral therapy (ART) for at least 12 months prior to screening and on a stable ART regimen for at least 8 weeks prior to screening (current ART regimen cannot include an Non-nucleoside reverse transcriptase inhibitor [NNRTI] or long-acting ART).
  • Negative human immuno-deficiency virus (HIV)-2 antibody (Ab)
  • Cluster of differentiation 4 (CD4+) T cell count >= 500 cells/μL at screening and no known evidence of CD4+ T cell count < 500 cells/μL in the last 12 months prior to screening
  • Participant must have plasma HIV-1 ribonucleic acid (RNA) below the lower limit of quantitation (LLOQ) at screening and for at least 12 months prior to screening

Exclusion Criteria:

  • Prior exposure to long acting antiretrovirals within 24 weeks or within a period defined by 5 half-lives, whichever is longer, prior to randomization and prior to the first dose of study drug.
  • History of CD4+ T cell nadir of <= 200 cells/μL during chronic HIV infection.
  • History of medical disorders (other than HIV-1 infection) that, in the opinion of the investigator, might expose the participant to undue risk of harm, confound study outcomes or prevent the participant from completing the study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Arm A: Placebo

Participants will receive budigalimab placebo on Day 1, and Weeks 2, 4, and 6 in combination with ABBV-382 matching placebo on Day 1 and Weeks 4 and 8.

IV Infusion

IV Infusion

Eksperimentell: Arm B: Budigalimab Dose A

Participants will receive budigalimab Dose A on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 matching placebo Day 1 and Weeks 4 and 8.

IV Infusion

Intravenous (IV) Infusion

Andre navn:
  • ABBV-181

Subcutaneous (SC) Injection

Andre navn:
  • ABBV-181
Eksperimentell: Arm C: ABBV-382 Dose A

Participants will receive budigalimab placebo on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 Dose A on Day 1 and Weeks 4 and 8.

IV Infusion

IV Infusion

Eksperimentell: Arm D: Budigalimab Dose A + ABBV-382 Dose B

Participants will receive budigalimab Dose A on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 Dose B on Day 1 and Weeks 4 and 8.

Intravenous (IV) Infusion

Andre navn:
  • ABBV-181

Subcutaneous (SC) Injection

Andre navn:
  • ABBV-181

IV Infusion

Eksperimentell: Arm E: Budigalimab Dose A + ABBV-382 Dose A

Participants will receive budigalimab Dose A on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 Dose A on Day 1 and Weeks 4 and 8.

Intravenous (IV) Infusion

Andre navn:
  • ABBV-181

Subcutaneous (SC) Injection

Andre navn:
  • ABBV-181

IV Infusion

Eksperimentell: Arm F: Budigalimab Dose B

Participants will receive open-label budigalimab Dose B on Day 1 and Weeks 2, 4, and 6 (Note, no ABBV-382 or placebo will be administered).

Intravenous (IV) Infusion

Andre navn:
  • ABBV-181

Subcutaneous (SC) Injection

Andre navn:
  • ABBV-181

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of Participants With Viral Control Without Antiretroviral Therapy (ART) Restart
Tidsramme: Week 24

Percentage of participants who achieve viral control (viral load < 1000 copies/mL) without ART restart at Week 24.

Week 24
Number of Participants With Adverse Events (AEs)
Tidsramme: Up to approximately Week 112

An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Up to approximately Week 112

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Median Peak Log10 Viral Load (At Rebound) Prior to Re-Starting ART
Tidsramme: Up to 112 weeks

The median peak log10 viral load (at rebound) before re-starting ART.

Up to 112 weeks
Median Time to First Rebound to ≥ 1000 Copies/mL During ART Interruption
Tidsramme: Up to 112 weeks

The median time to first rebound to ≥ 1000 copies/mL during ART interruption.

Up to 112 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: ABBVIE INC., AbbVie

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

12. oktober 2023

Primær fullføring (Faktiske)

22. september 2025

Studiet fullført (Faktiske)

22. september 2025

Datoer for studieregistrering

Først innsendt

5. september 2023

Først innsendt som oppfylte QC-kriteriene

5. september 2023

Først lagt ut (Faktiske)

13. september 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

4. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • M19-965
  • 2023-505900-53-00 (Annen identifikator: EU CT)
  • 2023 (U.S. NIH-stipend/kontrakt)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

IPD-delingstidsramme

For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Tilgangskriterier for IPD-deling

To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere